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Abstract 
  
Introduction 
Since 2012 we have undertaken a programme of research into the management of 
hypertension in people with dementia[1]. As part of this we are studying the feasibility of 
withdrawing antihypertensive drugs in people with dementia and well-controlled 
hypertension, with the aim of them remaining normotensive but avoiding some of the 
burdens and side-effects of antihypertensive medications. We decided to undertake a 
preliminary examination of the literature to examine the evidence and safety of 
antihypertensive withdrawal (not restricted to those with dementia) to determine 
whether this has already been extensively reviewed, to provide an approximate estimate 
of the likelihood of success of antihypertensive withdrawal, and to prepare for a 
systematic review of this literature if required and feasible. 
 
Method  
For this rapid review, we undertook a search for existing reviews and examined the 
relevant papers identified, and briefly updated the search once we found that the most 
recent review was in 2008.  
 
Results 
One appropriate review (from 2008) yielding seven relevant articles, and one further 
article were identified, giving eight articles which were examined. Seven of the eight 
were published more than ten years ago. Six of the eight studies had follow-up data for 
1 year or longer. Successful long term (1 year or more) withdrawal of antihypertensive 
medication was reported in 20-52% of patients.  
 
Conclusion 
Our review indicates that 22-50% of patients whose blood pressures are currently 
adequately controlled might be able to withdraw medication without return of long term 
hypertension. The rapid review approach we took may have missed articles of relevance 
and so we propose that a systematic review of withdrawal is undertaken. Because much 
of the data will be old, it should seek data not only on the proportions of patients who 
remained normotensive at long term follow up using the standards of the day, but 
should seek data on findings relevant to current guidelines. Only data reporting long 
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term follow up (≥ 1 year) should be included. Data referring to old or discontinued 
medications should be distinguished.  
 
 
Introduction 
 
Our research group is undertaking a programme of research into the management of 
hypertension in people with dementia. We recognise that it is now widely accepted that 
advanced age alone is not a contra-indication to the treatment of hypertension. UK 
guidelines produced by the National Institute for Health and Care Excellence (NICE) for 
the management of hypertension and European guidelines for the management of 
arterial management of hypertension differ according to age (above and below 80) and 
the presence of diabetes[2 3]. The guidelines advise that co-pathology is taken into 
account in those aged over 80, but there is no specific guidance about how to amend 
treatment in the context of co-morbidity other than adjustment of pharmacotherapy in 
those with clinical features of symptomatic orthostatic hypotension. There is no specific 
guidance for the treatment of hypertension in people with dementia. 
 
The management of hypertension in those with dementia is uncertain. Although 
hypertension increases the risk of dementia[4] it is still unclear if it affects dementia 
progression[5 6]: lowering blood pressure levels could protect against ischaemic damage 
but could also increase the risk of hypo-perfusion damage. There is very little evidence 
of treatment benefit in people with dementia[6] largely because such people were 
excluded from most trials of antihypertensive therapy. People with dementia may be at 
higher risk of the adverse effects of antihypertensive therapy[7]. 
 
Given this uncertainty, it may be helpful to ensure that all people with dementia given 
antihypertensive therapy actually need them to control their hypertension: if the drugs 
can be removed or reduced, the risks from them can be abolished or diminished. This 
might be possible because some patients may have been spuriously diagnosed with 
essential hypertension due to the “white coat” effect. There is also a tendency for blood 
pressure levels to fall with the development of dementia so some of those who were 
previously hypertensive may become normotensive over time[8]. 
 
For these reasons our research programme examined the feasibility of a large controlled 
study of the withdrawal of antihypertensive medication in people with dementia. As part 
of this work, we sought to determine from previous literature what proportion of people 
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with hypertension can successfully withdraw anti-hypertensive medication without return 
of hypertension. We undertook a preliminary examination of the literature to examine 
the evidence and safety of antihypertensive withdrawal (not restricted to those with 
dementia) to determine whether this has already been extensively reviewed, to provide 
an approximate estimate of the likelihood of success of antihypertensive withdrawal, and 
to prepare for a systematic review of this literature if required and feasible.  
 
 
Method 
 
Our initial rapid review approach was to conduct a “review of reviews” by searching for 
existing reviews – which saves the time taken to undertake primary searches – and to 
select and examine papers from those reviews. As the only suitable review we found was 
in 2007, reflecting practice of at least a decade ago, we briefly searched for more recent 
articles using the search strategy reported in the 2007 review. 
   
The primary outcome measure for the review was the proportion of participants who 
could successfully withdraw their anti-hypertensive medications. Secondary outcomes 
included the definitions of normotension, safety of anti-hypertensive withdrawal, 
predictors of successful withdrawal and identification of clinical protocols used to 
withdrawn medications and monitor participants.  
 
Identification and selection of reviews 
 
The following databases were searched for reviews: 
 Ovid MEDLINE (R) In-Process & Other Non-Indexed Citations and Ovid Medline 
(R) 1946 to April 2014  
 PubMed 
 Database of Abstracts on Reviews and Effectiveness  
 Scopus 
 Web of Science 
 Cochrane Library 
 
The following terms were combined: antihypertensive.mp or antihypertensive agents 
AND withdrawal.mp AND review.pt AND english.lg and applied to each database in turn. 
Figure 1 outlines the searching procedure employed and process of study selection.  
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The following criteria were used to select reviews for examination: 
 
Inclusion criteria  
 review articles that quantify the success or failure of specific antihypertensive 
drug withdrawal regimes 
 including studies reporting on participants aged 65 years and older 
 
Titles and abstracts of published reviews were reviewed by two reviewers. Consensus 
was reached on review studies to exclude: full-text articles of the reviews were sought 
when abstracts were unclear or absent. Quality assessment of retained review papers 
was then undertaken independently by the pair of reviewers using the Critical Appraisal 
Skills Programme (CASP) Checklist for Review Articles[9]. The CASP tool for systematic 
reviews consists of 10 questions, of which seven or eight (depending on whether or not 
there was a meta-analysis) can be scored 0/1/2, giving a maximum score per paper of 
14-16 marks. We assigned a percentage rating to each review paper to allow for 
differences in the scoring system, and papers scoring above 50% that met the selection 
criteria were included in the present study. 
 
Selection of primary research articles from reviews papers 
Primary research articles were included where they presented data specific to our 
research question of interest. They had to report data specific to the older adult 
population, reporting on the rates of successful withdrawal. It was also necessary for 
them to report the effects of withdrawal of treatment for essential hypertension 
specifically, rather than just the effects of stopping these classes of medications 
prescribed for other reasons, e.g. ankle swelling, heart failure etc.  
 
Data extraction and analysis from included research articles 
Data were extracted to allow demographic characterisation of the recruited sample, 
including age and gender plus the healthcare setting where the study was performed. 
Data were then extracted for the pre-specified outcomes of interest. These were 
tabulated and a narrative synthesis performed.  
 
 
Results 
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Figure 1 shows the search results and selection process. 23 reviews were identified, of 
which only eight were relevant and only one met our quality criteria, a review by Iyer 
and colleagues published in 2008[10]. 
 
Iyer et al. presented the results of 13 withdrawal studies, the full-texts of which were 
obtained for review. Four of the studies were randomised, double-blind, placebo-
controlled studies which looked at the withdrawal of diuretics[11-14] and the remaining 
nine were prospective observational studies[15-23]. Six of the 13 withdrawal studies 
were not suitable for our purposes as they concerned withdrawal of diuretics prescribed 
for ankle oedema[12], exclusion of participants who were prescribed loop diuretics for 
hypertension [11] and a lack of included data on the successful withdrawal of medication 
for the treatment of essential hypertension[13 14 21 23].  
 
As the retained review only searched the literature until 2007, we replicated Iyer et al.’s 
search strategy[10] for the period January 2007 – May 2014, to establish if any studies 
had been published since the review was published, combining the search terms: 
‘withdrawal OR stop OR cessation OR discontinue AND anti-hypertensive’. We limited this 
search to studies conducted on human subjects including adults >65 years and excluded 
case reports.  
 
This search resulted in 229 results in PubMed and 88 in Ovid MEDLINE (Figure 2). The 
titles were reviewed by two reviewers and two articles were retained and reviewed, 
Hajjar and van Duijn[24 25]. However, although van Duijn et al. included participants up 
to the age of 75, they did not present withdrawal results specifically for the older adult 
population and so it was excluded[25]. 
 
Thus, in total we examined eight primary research studies. 
 
Study characteristics 
The studies were published between 1983 and 2013. The studies reported upon a total 
of 7989 participants. The mean age of participants ranged from 71-75 years and all 
comprised a female-predominant population. Follow-up ranged from three weeks to five 
years, with a mean follow-up period of 1.6 years. Five of the studies were conducted as 
part of run-in or preparatory phases before the onset of a new clinical trial of anti-
hypertensive medication [15 17 19 20 24]. The largest study Nelson (b) accounted for 
86% of participants and followed-up participants for a median of four weeks[20]. 
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The studies were conducted in a range of healthcare settings, recruiting from general 
practice, hospital inpatients, and outpatient clinics but not institutional care (care 
homes). Studies tended to recruit a highly selected study population, with one (Ekbom) 
necessitating that participants be healthy and independent[15] and another (Lernfelt) 
that they have no evidence of cardiovascular disease[17]. Study findings are 
summarised in Tables 1, 2 & 3.  
 
Successful anti-hypertensive withdrawal  
The proportions of participants who had anti-hypertensive medication successfully 
withdrawn are tabulated in Table 2, comparing the follow-up and definition of 
normotension applied in each study. 
 
Two studies provided data on short term withdrawal only (Hajar, Nelson b). Despite such 
short follow-up, Nelson and colleagues (Nelson b) only found that 9.4% of patients 
remained with a blood pressure of 140/80 or less after a median of four weeks follow up. 
 
The other six studies provide follow-up of at least one year and reported successful 
withdrawal of 27-52% of participants at one to three years, using criteria for success 
that varied from a systolic BP of 160 to 230. 
 
In summary, successful long term (1-3 years) withdrawal of antihypertensive medication 
was reported in 27-52% of patients. A discrepant finding was Nelson b,[20] who showed 
only a 9-18% successful withdrawal rate (depending upon the cut off for success used) 
by four weeks: this was by far the largest study in our review.  
 
Safety of anti-hypertensive withdrawal  
The safety data relating to anti-hypertensive withdrawal was varied and summarised in 
Table 3.  No standard approach to reporting safety data was identified across the 
included studies, and so we included any descriptive or quantitative data relating to 
adverse events. One study defined pre-specified end-points (e.g. myocardial infarction, 
stroke etc.)[18] but there were no such events; a second study defined serious adverse 
events, including myocardial infarction, angina and left ventricular failure and reported a 
2.3% adverse event rate. The remaining studies which reported safety data simply 
present the total numbers of participants who either died or experienced an adverse 
event without reporting which intervention they received[17 19]. 
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One study modelled the likelihood of adverse events and survival following anti-
hypertensive withdrawal[15]. It reported that 22.2% of participants died in the study 
period. However, those who had withdrawn from medication were at lower risk of 
cardiovascular events and death than those who remained on them[15]. 
 
Predictive factors for successful withdrawal  
Three of the studies reported that participants were more likely to have their anti-
hypertensive therapy successfully withdrawn if they were on monotherapy[15 19 20].  
Lower age was also identified as a predictor of more successful withdrawal in two of the 
studies with those aged 65-74 more successful than older participants[19 20]. A low 
baseline blood pressure was also a predictor of successful withdrawal[15]. 
One study identified that withdrawal of α- and β-blockers were associated with higher 
rates of withdrawal failure[20]. However, a second study identified more likelihood of 
successful withdrawal among male compared to female participants and identified male 
participants were most commonly prescribed β-blockers[18].  
 
Timing of return of hypertension  
The early return of hypertension was a common feature, with three studies reporting a 
higher rate of developing hypertension within the first few weeks/month compared to 
later follow-up progressed[15 16 19]. The most marked difference was found by Nelson 
(a) who reported 50% returned to hypertension in the first 70 days, compared to 11% 
from days 200-400[19].  
 
Use of clinical protocols 
Half of the studies explicitly stated their procedure for anti-hypertensive withdrawal, of 
which one specified this was done ‘gradually under supervision of a research nurse’[19] 
and one described ‘a wash-out over a three month period’[15]. The other two specified 
the precise regime for dose reduction[20 24] and one expressed a preference for holding 
the withdrawal of β-adrenoceptor blockers or diuretics until last if the patient is on 
multiple medications[20]. 
 
One study supplemented researcher-recorded blood pressure measurements with 
participant automated measurements twice daily[24]. This procedure appeared to be 
feasible and rate of BP diary recording was 74%[24].Two studies required the agreement 
and active participation of the participant’s primary care physician in completion of the 
withdrawal programme[20 24] or in monitoring after withdrawal[16 19]. 
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Discussion 
 
Using this rapid review technique we found eight studies that reported on the success of 
antihypertensive drug withdrawal, six of which presented long term data. The studies we 
examined gave a mixed picture: long term studies showed a successful withdrawal rate 
of 27-52% yet a single but very large study showed short term success rates of 9-18%. 
We found no evidence that successful withdrawal of antihypertensive therapy was 
unsafe, and some evidence that successful withdrawal was more likely in those on fewer 
agents and lower baseline blood pressures. Several months of follow-up is required to 
determine whether withdrawal has been successful, as half of those who become 
hypertensive after withdrawal do so after 10 weeks.  
 
There are considerable drawbacks to this rapid review technique, and we cannot claim 
that it will have identified all the potentially relevant information. We propose that a 
formal systematic review is undertaken given that no adequate and up to date one has 
yet been conducted. The experience gained from this rapid review can guide the 
development of the protocol for a systematic review and can be used to check the 
adequacy of any future search strategy. Most papers identified in this review reported on 
practice from more than 10 years ago. The fact that treatment thresholds were higher in 
the past than they are today should not affect the proportion of patients who can 
withdraw and so this fact alone does not invalidate the relevance of the findings to 
modern practice. However, older studies will have used different drugs and different 
methods for the determination of blood pressure than used currently (such as 
ambulatory BP measurements) and so the findings may not directly apply to current 
practice.   
 
Given the limitations of the review and the uncertainty of the findings, we recommend 
that a formal systematic review is conducted. Widespread searching will be required, 
particularly looking at the preparatory phases of trials of newer antihypertensive agents. 
Data should be sought from such studies that define how blood pressure was measured, 
the agents in use, the actual follow up blood pressures over time, and precise definitions 
of successful withdrawal. Another approach that could shed light upon the degree to 
which antihypertensive medication can be withdrawn without the return of hypertension 
might be afforded by new primary studies of GP databases, since we are aware that 
many people withdraw antihypertensive treatment as part of clinical practice (for 
example due to poor compliance, decline of consent, or adverse drug reactions) – 
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although this would not represent the effects of a systematic programme of withdrawal 
of antihypertensive medications in the absence of a clinical indication.  
 
From the perspective of our research programme into the management of hypertension 
in people with dementia, these observations remind us that a primary problem is that we 
are still not sure if the benefits of treating hypertension outweigh the risks in people with 
dementia. Given that it is unlikely that adequately powered placebo controlled trials of 
antihypertensive therapy in this group will be feasible, we recommend that further 
studies in this area seek to perform epidemiological studies using large databases of 
existing practice of to examine the relationships between patient and medication factors 
and adverse outcomes including death, and vascular events but also other events of 
importance to people with dementia such as falls and institutionalisation. Modelling 
studies, informed by information from epidemiological studies might be able to identify 
clinical subgroups in which the risks of treatment offset or outweigh its benefits. Given 
the uncertainty of the benefit to risk ratio, it will also be useful to continue to work on 
means of reducing the risks of antihypertensive therapy and identifying those at high 
risk of an adverse drug reaction, for example by using ambulatory or home blood 
pressure monitoring to detect excessive blood pressure variability, or episodes of 
significant hypotension. 
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Figure 1 Summary of search and selection process 
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Figure 2 Update search 
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Table 1 Antihypertensive withdrawal study characteristics 
Study  Date Country Healthcare  
Setting 
Study  
Design 
Number of 
Participants 
Withdrawal 
Attempted 
Other  
Patient 
 Characteristics 
Ekbom[15] 1994 Sweden Community Prospective observational cohort 333 Mean age 75.2 years; 68% female 
Participants recruited were relatively healthy 
and independent 
Hajjar[24] 2013 USA Community  ‘Taper phase’ of randomised controlled 
trial (before randomisation) 
53 Mean age 71 years; 64% female 
Hansen[16] 1983 Denmark Inpatients & 
outpatients 
Prospective observational cohort 105 Mean age 75 years 
No gender data presented for cohort 
Lernfelt[17] 1990 Sweden Community Prospective observational cohort 25 All aged >70 years; 60% female 
Treatment for 4-30 years (mean 11.6) 
Nadal[18] 1994 Sweden Outpatients Prospective observational cohort 86 Mean age 74 years; 62% female 
Treatment for 3-36 years (mean 20) 
BP at start of follow-up SBP160 +/-3 in males, 
169+/-3 in females. DBP 91+/-1 
Nelson 
(a)[19] 
2002 Australia General practice Prospective observational cohort 503 Median age 71 years; 83% female 
Nelson 
(b)[20] 
2003 Australia General practice Prospective observational cohort 6833 Mean 71.9 years; 56% female 
Mean SBP 146.7 DBP 80.6 
van 
Kraaij[22] 
1997 The 
Netherlands 
Inpatients & 
outpatients 
Retrospective analysis of case records and 
1-year follow-up 
51 Withdrawal in 218 participants of whom 72% 
female, all over 75 years of age 
51 of 218 withdrawn for hypertension 
 
ISSN: 2059-3341 
EMRAN: Antihypertensive withdrawal 
www.nottingham.ac.uk/emran 
 
p 14 
 
 
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. 
To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ . 
 
 
  
Table 2 Successful withdrawal by follow-up and BP criteria 
 
Study Name & Date Proportion withdrawn successfully Time of  
follow-up 
BP Criteria Used Mean End of Study BP  
(Off-AHT Treatment) 
Ekbom 1994[15] 40%  
20%  
1 year 
5 years 
SBP 180-230 with DBP of at least 90 OR 
DBP 105-120 on three occasions 
169/88 
Hajjar 2013[24] 100%  
 
3-4 weeks >180/100 on two occasions Up by 12/6 
Hansen 1983[16] 41%   1 year DBP 110 160/90 
Lernfelt 1990[17] 32%   2 years SBP 200 OR 
DBP 105 
Up by 23.8/9.6 
Nadal 1994[18] 60%   
27% (of those withdrawn successfully at 1 month) 
1 month 
3 years 
Not reported Not reported 
Nelson (a) 2002[19] 36%  1 year SBP 160 OR  
DBP 90 where SBP 140 
SBP <160 and DBP <90 
Nelson (b) 2003[20] 18% (Using 160/90mmHg)  
9.4% (Using 140/90mmHg)  
Median 4 weeks 
(Range: 0-76) 
SBP 160 OR  
DBP 90 where SBP 140 
Not reported 
van Kraaij 1997[22] 52%  1 year Not reported Not reported 
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Table 3 Further results of withdrawal studies 
 
Study  Safety Drugs Timing of Return of  
Hypertension 
Withdrawal Protocol Other  
Comments 
Ekbom[15]  74/333 (22.2%) died during study period 
Lower rate of cardiovascular events in 
those without treatment  
Monotherapy 
associated with 
successful withdrawal 
10% restarted medication 
within the first month 
60% restarted medication 
within the first year 
Wash-out of medications over a 3-month period  
Exclusion criteria/failure if supine SBP on 3 separate 
occasions was 180-230mmHg with a DBP of at least 90 
OR if DBP was between 105-120mmHg 
Successful withdrawal associated with lower 
blood pressure before withdrawal 
Cohort of participants recruited for STOP-
Hypertension study 
Hajjar[24] No participants experienced headaches, 
dizziness, visual changes or focal 
weakness  
Mean BP increase 12/6mmHg in 4 weeks 
2% of readings exceeded 180/100mmHg 
No specific class effects 
identified 
No data provided Dose reduction and cessation over 3 weeks  
Week 1: reduction 25-50%, Week 2: reduction 50-75%, 
Week 3: off all medications 
Participants completed automated home BP monitoring 
Preparation for participation in The 
Antihypertensives and Vascular, Endothelial 
and Cognitive Function Trial AVEC) 
Hansen[16]  No safety data reported  No specific class effects 
identified 
Most developed 
hypertension within 3 
weeks of withdrawal 
Protocol not described Target used was DBP of <110mmHg 
Lernfelt[17]  One death at 2 months due to MI; one 
episode of AF and heart failure at 4 
months 
Majority of participants 
prescribed ACE-i or 
diuretics 
No specific class effects 
identified as predictors 
Three developed 
significant hypertension 
within 6 months of 
withdrawal 
Protocol not described Conducted as part of longitudinal population 
study of ‘70-year-old people in Gothenburg, 
Sweden’ 
Only withdrew from those with ‘no signs of 
cardiovascular disease’ 
Nadal[18] No primary endpoints (MI, stroke or 
heart failure) occurred during study 
Most males were 
prescribed β-blockers, 
females were 
prescribed β-blockers 
and diuretics 
No data provided In first month BP was checked fortnightly 
Monthly over following three months and twice yearly 
thereafter 
No drug withdrawal protocol provided 
More males remained normotensive than 
females (62 vs. 11%) 
Nelson 
(a)[19] 
Four participants died (two with vascular 
events) 
Single drug treatment 
associated with more 
successful withdrawal 
Most returned to 
hypertension within the 
first 100 days 
 
Treatment ‘gradually withdrawn under supervision of a 
research nurse’. Seen weekly during withdrawal until a 
minimum of two weeks after cessation of all medications 
Normotension: sitting SBP <160mmHg and DBP 
<90mmHg 
Medications re-initiated by participant’s own GP 
Participants drawn from those volunteering to 
participate in the second Australian National 
Blood Pressure Study 
Those aged 65-74 were more likely to remain 
normotensive than those 75-84yrs 
Nelson 
(b)[20]  
2.3% of participants experienced a 
serious adverse event.  
2.5% of normotensive group vs. 1.5% 
who became hypertensive vs. 9.6% who 
exited during withdrawal  
Monotherapy 
associated with 
successful withdrawal 
Use of β or α blockers 
associated with failure 
No data provided Family physicians given guidance 
Stepwise withdrawal (i.e. one drug at a time, half doses 
at weekly intervals to the lowest usual therapeutic dose 
then cease and withdrawal of β-adrenoceptor blockers 
or diuretics last if patient on more than one medication) 
Run-in phase of Second Australian National 
Blood Pressure Study 
Definition of hypertension revised to more 
modern cut-point of 140 latterly and data 
presented for both 
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to withdraw Study nurse monitored BP at weekly intervals 
Hypertension defined ≥160mmHg systolic or ≥90mmHg 
diastolic (if SBP ≥140mmHg).  
Younger participants more likely to remain 
normotensive 
van 
Kraaij[22] 
Data not specific for AHT withdrawal Data not specific for 
AHT withdrawal 
Data not specific for AHT 
withdrawal 
Protocol not described 101/218 (46%) indication for diuretic therapy 
was unclear 
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